Scientific Health Development

Scientific Health Development ("SHD") is a boutique investment company located in Dallas, TX. SHD invests in early-stage, innovative healthcare-related technologies and products.


Recent News

Boston Therapeutics Announces Strategic Acquisition of CureDM

Lawrence, MA - February 13, 2018 -- Boston Therapeutics, Inc. (Boston Therapeutics) announces the acquisition of CureDM Group Holdings, LLC (CureDM), adding a Phase 2-ready drug to their portfolio. The CureDM islet-growing peptide, HIP2B, has demonstrated clinical efficacy for type 2 diabetes by improving first phase insulin release, increasing fasting insulin levels and insulin secretion rates. Boston Therapeutics is committed to development of treatments that impact endogenous glucose regulation. This bold move to acquire the worldwide exclusive rights to commercialize HIP2B, alongside current product offerings, is a key part of the long term plan to alleviate the health, economic and quality of life burden of diabetes. For full story click here...

Procyrion raises $16m in Series C to support Aortix intra-aortic heart pump

Houston, TX - February 1, 2018 -- Procyrion said earlier this week it raised $16 million in a Series C round of funding to support its Aortix catheter-deployed, intra-aortic heart pump designed for ambulatory use. The round was led by an affiliate of Fannin Partners and joined by existing investors Scientific Health Development, the State of Texas and an undisclosed strategic investor, the Houston-based company said. For full story click here...

Sight Sciences Expands Surgical Portfolio with FDA Clearance of the OMNI™ Surgical System

Menlo Park, CA - January 4, 2018 -- Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic device company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its OMNI™ Surgical System, a surgical tool dually indicated for the delivery of controlled volumes of viscoelastic fluid as well as the cutting of trabecular meshwork tissue. In addition, the company announced three key hires who possess proven leadership capabilities and industry experience to advance the commercial strategy and build out its senior leadership team. For full story click here...

Channel Medsystems® Secures $14.1mm Financing for Office-Based Treatment of Heavy Menstrual Bleeding

Emeryville, CA - August 23, 2017 -- Channel Medsystems, developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced today that it has secured a $14.1mm Series C-1 financing. The insider-led round included participation by Third Point Ventures, InCube Ventures, Aperture Venture Partners, Scientific Health Development, Longwood Fund, and Boston Scientific. For full story click here...

Complexa Raises $62 Million in Series C Financing to Test CXA-10 in Two Orphan Disease Proof-of-Concept Trials

Radnor, PA - July 26, 2017 -- Complexa Inc., a clinical stage biopharmaceutical company, today announced the completion of a $62 million Series C funding round led by New Enterprise Associates (NEA) and Pfizer Venture Investments, LLC. Participation in this round also included Edmond de Rothschild Investment Partners, HBM Healthcare Investments and existing investors including JAFCO Co., Ltd. (JAFCO), which led the Company's Series B financing in 2014. For full story click here...

Podimetrics Publishes Landmark Study Demonstrating 97% Sensitivity in Predicting Emergence of Diabetic Foot Ulcers Five Weeks Prior to Clinical Presentation

Somerville, MA - June 29, 2017 --Podimetrics, Inc., a medtech and services company focused on the early detection and prevention of diabetic foot ulcers (DFU), announced today the publication of a landmark study in the July issue of Diabetes Care. Results demonstrate that the Podimetrics SmartMat™ detected as many as 97% of developing nontraumatic plantar foot ulcers on average five weeks before they presented clinically. Importantly, 86% of patients used the mat at least three times per week and 88% of respondents reported it being easy-to-use, suggesting that patients readily accept this practical, new monitoring technology. For full story click here...

Channel Medsystems® Earns CE Mark Approval for the Cerene® Cryotherapy Device

Emeryville, CA - June 26, 2017 -- Channel Medsystems, the developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced today that it has earned CE Mark approval, allowing the Company to initiate marketing efforts and commercialization of its Cerene Cryotherapy Device (Cerene device) in Europe. The Cerene device is intended for endometrial cryoablation in premenopausal women with heavy menstrual bleeding due to benign causes in whom childbearing is complete. For full story click here...

Potrero Study Demonstrates New Standard of Care for Accurately Measuring Intra-Abdominal Pressure in Critical Care Patients

Northfield, IL - June13, 2017 --The prevalence of intra-abdominal hypertension (IAH) in the critically ill is reported to be as high as 50 percent and is a significant cause of abdominal compartment syndrome (ACS), morbidity and mortality. Diagnosis requires an accurate, reliable and consistent standardized methodology for measuring intra-abdominal pressure (IAP). The accuracy of the intra-vesical pressure (IVP) method, the current standard-of-care measurement method, is hindered by “self-assembly” set-up, which is performed manually and introduces non-standardized construction, clinical technique and quality control challenges. It is often time-consuming, leads to errors and can put patients at risk for infection. For full story click here...

Sight Sciences Announces Health Canada Approval of the VISCO™360 Viscosurgical System for Standalone Microinvasive Glaucoma Surgery (MIGS)

Menlo Park, CA - April 13, 2017 -- Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced today that it has received Health Canada approval for the VISCO™360 Viscosurgical System. The VISCO360 System is indicated in Canada for the microcatheterization and transluminal viscodilation of Schlemm's canal to reduce intraocular pressure (IOP) in adult patients with open-angle glaucoma.* Performed as a standalone MIGS procedure, the first commercial VISCO360 cases in Canada were successfully carried out by Dr. Ike Ahmed, world-renowned ophthalmologist recognized for his extensive experience in the diagnosis and surgical treatment of glaucoma. For full story click here...

Channel Medsystems Completes Treatments in Largest Single-Arm Pivotal Study of Endometrial Ablation; Demonstrates Feasibility of Comfortable, Office-Based Procedure

Emeryville, CA - March 20, 2017 -- Channel Medsystems, the developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced the successful completion of the treatment phase in its CLARITY Pivotal Study. The goal of the CLARITY study is to evaluate the safety and effectiveness of the Cerene® Cryotherapy Device (Cerene device) in 242 women with heavy menstrual bleeding who are finished with childbearing. For full story click here...

Medline Joins Forces with Potrero Medical to Transform Critical Care Monitoring

Northfield, IL - January 23, 2017 -- Medline Industries, Inc., a leading global healthcare manufacturer and distributor, and Potrero Medical, Inc., a privately held medical device company and the developer of the Accuryn™ critical care monitoring system, today announced a joint partnership to expand commercialization and continue clinical investigations to further support the benefits of the Accuryn critical care monitoring system. For full story click here...

Sight Sciences Announces Health Canada Approval of the TRAB™360 Trabeculotomy System

Menlo Park, CA - December 23, 2016 -- Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received Health Canada approval for the TRAB™360 Trabeculotomy System. The TRAB™360 is indicated in Canada for the microcatheterization of Schlemm's canal and cutting of trabecular meshwork to lower intraocular pressure (IOP) in patients with primary open angle glaucoma. From a single clear corneal incision, the TRAB™360 surgeon can complete a 360-degree trabeculotomy. For full story click here...

Channel Medsystems Secures IDE Approval and Treats First Women in the CLARITY Pivotal Study

Emeryville, CA - November 14, 2016 -- Channel Medsystems, the developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced the treatment of the first subjects in the US phase of its CLARITY Pivotal Study. CLARITY is a multicenter study to evaluate the safety and effectiveness of the Cerene™ Cryotherapy Device for endometrial ablation in women with heavy menstrual bleeding who are finished with childbearing. For full story click here...

Azevan Pharmaceuticals Reports Positive Phase 2 Exploratory Clinical Study Results with SRX246 in Intermittent Explosive Disorder

Bethlehem, PA - September 14, 2016 -- Azevan Pharmaceuticals, Inc. (www.azevan.com) announced results from the phase 2 exploratory clinical study of the Company's lead compound, SRX246, in adults with Intermittent Explosive Disorder. The study was a multi-center, randomized, double blind, placebo controlled trial in 97 adult male and female subjects. It included a two-week placebo lead-in phase and then randomization to SRX246 or placebo for 8 weeks. For full story click here...

Sight Sciences Announces CE Mark Approval for and Successful Commercial Experiences with the VISCO™360 Viscosurgical System for the Surgical Treatment of Glaucoma

Menlo Park, CA - September 9, 2016 -- Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced today that the initial European commercial cases with the CE mark approved VISCO™360 Viscosurgical System will be presented Monday morning, September 12th during the European Society of Cataract and Refractive Surgeons (ESCRS) meeting in Copenhagen, Denmark. For full story click here...